Vitura Health Ltd
ASX:VIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (6.7), the stock would be worth AU$-0.04 (197% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -6.9 | AU$0.04 |
0%
|
| 3-Year Average | 6.7 | AU$-0.04 |
-197%
|
| 5-Year Average | 9.9 | AU$-0.05 |
-243%
|
| Industry Average | 14.7 | AU$-0.08 |
-312%
|
| Country Average | 21 | AU$-0.11 |
-403%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Vitura Health Ltd
ASX:VIT
|
24.5m AUD | -6.9 | 33.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 34.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 19 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.8 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 42.2 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 11.6 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.2 |
| Median | 21 |
| 70th Percentile | 32.6 |
| Max | 583 153.2 |
Other Multiples
Vitura Health Ltd
Glance View
Vitura Health Ltd. operates as a medicinal cannabis company. The firm through its wholly owned subsidiary, CDA Health Pty Ltd, operates businesses, such as Burleigh Heads Cannabis and CDA Clinics. Burleigh Heads Cannabis operates the prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes approximately 200 product stock-keeping units (SKUs) within Australia from 30 international and domestic medicinal cannabis producers. CDA Clinics undertakes telehealth consultations with patients seeking access to medicinal cannabis. Its portfolio of brands includes CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc and Adaya. The firm owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
